

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 06/26/2001 09/891,206 Nigel D. Atherton PHARMA-131 9337 7590 EXAMINER 24999 07/12/2004 MILLEN, WHITE, ZELANO & BRANIGAN, PC PAK, JOHN D 2200 CLARENDON BLVD ART UNIT PAPER NUMBER **SUITE 1400** ARLINGTON, VA 22201 1616

DATE MAILED: 07/12/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

01 - •	Application No.	Applicant(s)	
Office Action Summary	09/891,206	391,206 ATHERTON ET AL.	
	Examiner	Art Unit	
	JOHN D PAK	1616	
The MAILING DATE of this communicat Period for Reply	ion appears on the cover sheet wi	th the correspondence address	
A SHORTENED STATUTORY PERIOD FOR THE MAILING DATE OF THIS COMMUNICA - Extensions of time may be available under the provisions of 37 after SIX (6) MONTHS from the mailing date of this communic - If the period for reply specified above is less than thirty (30) da - If NO period for reply is specified above, the maximum statutor - Failure to reply within the set or extended period for reply will, Any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).	TION. 7 CFR 1.136(a). In no event, however, may a ration. 19s, a reply within the statutory minimum of third properties of the statutory minimum of the properties of the statutory minimum of the properties of the statute. Cause the application to become AB	eply be timely filed y (30) days will be considered timely. THS from the mailing date of this communication ANDONED (35 U.S.C. § 133).	on.
Status			
1)⊠ Responsive to communication(s) filed o	n <u>21 April 2004</u> .		
2a) This action is FINAL. 2b)	oxtimes This action is non-final.		
3) Since this application is in condition for closed in accordance with the practice to	•	·	is
Disposition of Claims			
4) ☐ Claim(s) 1,2,7-19,22-24 and 26-55 is/ar 4a) Of the above claim(s) 22 and 33 is/a 5) ☐ Claim(s) 1,2,7,8,10-19,26-32,36-40,42-46) ☐ Claim(s) 9,23,24,34,35,41 and 48 is/are 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction	are withdrawn from consideration. 47 and 49-55 is/are allowed. a rejected.		
Application Papers			
9) ☐ The specification is objected to by the E	xaminer.		
10) The drawing(s) filed on is/are: a)	accepted or b) objected to	by the Examiner.	
Applicant may not request that any objection	n to the drawing(s) be held in abeyar	ce. See 37 CFR 1.85(a).	
Replacement drawing sheet(s) including the 11) The oath or declaration is objected to by	·	•	(d).
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for a a) All b) Some * c) None of: 1. Certified copies of the priority doc 2. Certified copies of the priority doc 3. Copies of the certified copies of the application from the International * See the attached detailed Office action for	cuments have been received. cuments have been received in A he priority documents have been Bureau (PCT Rule 17.2(a)).	pplication No received in this National Stage	
Attachment(s)			
1) Notice of References Cited (PTO-892)		ummary (PTO-413))/Mail Date	
 Notice of Draftsperson's Patent Drawing Review (PTO-13) Information Disclosure Statement(s) (PTO-1449 or PTC Paper No(s)/Mail Date 		formal Patent Application (PTO-152)	

Application/Control Number: 09/891,206

Art Unit: 1616

Claims 1-2, 7-19, 22-24, 26-55 are pending in this application.

Claims 22 and 33 stand withdrawn as being directed to non-elected subject matter. Cancellation of the non-elected claims is suggested. Claims 1-2, 7-9, 23-24, 26-32 and 34-55 will presently be examined.

Claims 1-2, 7-8, 10-19, 26-32, 36-40, 42-47 and 49-55 are allowed.

Claim 9, 23-24, 34-35, 41 and 48 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 9 recites "chelates and derivatives thereof." This makes the claim indefinite and unclear because it cannot be determined what the metes and bounds of this genus of substances are. What is intended by "derivatives," and how much "derivation" is encompassed? Claim 9 is therefore indefinite.

Claim 9 contains a misspelling, "absorbants" (emphasis added). It should be --absorbents --- .

Claim 23 was not properly amended – the term "treat" is missing at line 2, after "manage or". Claim 34 is included here because it depends on claim 23 without correcting the deficiency of claim 23.

Claim 24 is confusing in that it is directed to a method for activating osteoblastic differentiation, but the last phrase recites, "optionally activating osteoblastic

Application/Control Number: 09/891,206

Art Unit: 1616

Page 3

differentiation." Claim 35 is included here because it depends on claim 24 without correcting the deficiency of claim 24.

Claim 41 contains a misspelling, "redodelling". There should be only one "I".

Claim 48 lacks antecedent basis for "said human." Change to "said mammal" is suggested.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to JOHN PAK whose telephone number is (571)272-0620, effective February 3, 2004. The Examiner can normally be reached on Monday to Friday from 8 AM to 4:30 PM.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's SPE, Thurman Page, can be reached on (571)272-0602, effective February 3, 2004.

The fax phone number for the organization where this application or proceeding is assigned is (703)872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571)272-1600.

JOHN PAK PRIMARY EXAMINER GROUP 1600